P 094Acetyl tetrapeptide-5

अनुक्रम से निर्मित आदर्श अनुरूपक; कोई प्रायोगिक या पूर्वानुमानित संरचना नहीं.

P 094 · 2Dरासायनिक संरचना (2D)

पबकेम स्माइल्स से 2डी चित्रण

P 094सत्यापित 2026-08-06

अनुसंधान बाजार

Acetyl tetrapeptide-5

उपनाम: Eyeseryl

Cosmetic ingredient marketed specifically for periorbital anti-edema and anti-glycation effects; listed in EU CosIng.

कॉस्मेटिक और अन्य

पहचान रिकार्ड

वर्ग: cosmetic other
अवशेष: दर्ज नहीं
PubChem CID: 11620163
सत्यापन: 2026-08-06
संशोधन: N-terminal acetylation; molecular formula C₂₀H₂₈N₈O₇

Ac-βAla-His-Ser-His (acetyl-β-alanyl-histidyl-seryl-histidine)

सरल भाषा में

यह पृष्ठ Acetyl tetrapeptide-5 का एक संरचित अनुसंधान सारांश है: यह क्या है, क्षेत्राधिकार के अनुसार इसकी अनुमोदन स्थिति, यह कैसे काम करता माना जाता है, प्रत्येक दावा किए गए उपयोग के पीछे का प्रमाण, और सुरक्षा व विनियमन के बारे में जो ज्ञात है।

प्रत्येक दावा किया गया उपयोग अलग से A (लेबल किए गए उपयोग के लिए स्थापित) से X (खंडित या असमर्थित) तक ग्रेड किया जाता है; ग्रेड एक दावे पर लागू होता है, पूरे यौगिक पर नहीं। अनुमोदन स्थिति और प्रमाण ग्रेड अलग-अलग प्रश्नों के उत्तर देते हैं।

इस पृष्ठ से: Best-supported claim on this page: Reduction of under-eye puffiness (Grade C), with the listed limitations.

यह कोई व्यक्तिगत सिफारिश नहीं करता: अनुमोदित खुराक केवल वर्तमान आधिकारिक लेबल से सारांशित होती है, अध्ययन किए गए रेजिमेन का वर्णन किया जाता है, अनुशंसा नहीं की जाती, और गैर-अनुमोदित यौगिकों पर लिखा होता है “No established or recommended human dose.”

शब्द नया लगे? शब्दावली खोलें

साक्ष्य सामग्री अंग्रेजी में रखी जाती है।

Acetyl tetrapeptide-5 के लिए आदर्श संरचना चित्रण — अनुक्रम से निर्मित आदर्श अनुरूपक; कोई प्रायोगिक या पूर्वानुमानित संरचना नहीं.

एक नज़र में

ENTRY TYPE: research market
IDENTITY: Sequence verified
TOP EVIDENCE: Grade C — Reduction of under-eye puffiness
MAJOR STATUS: Jurisdiction-specific — see status table
SPORT: Prohibited — as of 2026-08-06
VERIFIED: 2026-08-06

Bottom line

Acetyl tetrapeptide-5 (INCI name; trade name Eyeseryl) is a synthetic acetylated tetrapeptide (Ac-βAla-His-Ser-His) developed by Lipotec/Lubrizol specifically for periorbital cosmetic use. Its proposed mechanisms — reducing vascular permeability via angiotensin-converting enzyme (ACE) inhibition and inhibiting non-enzymatic protein glycation — target fluid accumulation and tissue stiffening under the eyes. A manufacturer-sponsored study of 20 volunteers using a formulation described as 10% Eyeseryl solution reported improvement in under-eye puffiness in 70% of subjects by day 15 and 95% by day 60. Evidence is limited to this single small, uncontrolled study. The ACE-inhibitory mechanism is plausible based on in vitro binding data but has not been confirmed in vivo after topical application.

Identity and composition

Field	Verified information
Preferred name	Acetyl tetrapeptide-5
Key aliases	Eyeseryl
Molecular/sequence identity	Ac-βAla-His-Ser-His (acetyl-β-alanyl-histidyl-seryl-histidine)
Modifications/form	N-terminal acetylation; molecular formula C₂₀H₂₈N₈O₇
Stable identifiers	CAS 820959-17-9; CosIng ref 54142; UNII Y1DFQ308G8; : 11620163
Identity caveats	PubChem does not have a specifically curated record for acetyl tetrapeptide-5; CAS/UNII are the preferred identifiers. The Eyeseryl trade name refers to a formulated solution containing the peptide, not the pure substance.

Development and approval status

Jurisdiction	Status and indication	Product/source	As of
EU (CosIng)	Listed in the CosIng inventory; an INCI listing is an inventory entry, not a regulatory authorisation or safety approval	INCI name: Acetyl Tetrapeptide-5; humectant function	2026-08-06
US (FDA)	Regulated as a cosmetic ingredient under the FD&C Act; not approved as a drug	FD&C Act	2026-08-06
EU (SCCS)	No specific SCCS safety opinion; covered under general provisions of EU Cosmetics Regulation EC 1223/2009	EU Cosmetics Regulation	2026-08-06
US (CIR)	No standalone Cosmetic Ingredient Review safety assessment for acetyl tetrapeptide-5 was identified in the sources searched; no CIR conclusion is inferred	CIR ingredient/publication search	2026-08-06

Status is multi-axis

Authorization belongs to the named product, use, place, and date; sport status is independent.

पाठ विकल्प

UNITED STATES: US (FDA): Regulated as a cosmetic ingredient under the FD&C Act; not approved as a drug; US (CIR): No standalone Cosmetic Ingredient Review safety assessment for acetyl tetrapeptide-5 was identified in the sources searched; no CIR conclusion is inferred
EU/EEA: EU (CosIng): Listed in the CosIng inventory; an INCI listing is an inventory entry, not a regulatory authorisation or safety approval; EU (SCCS): No specific SCCS safety opinion; covered under general provisions of EU Cosmetics Regulation EC 1223/2009
UNITED KINGDOM: No UNITED KINGDOM row is present in the source status table
OTHER DOCUMENTED: No OTHER DOCUMENTED row is present in the source status table

Sport status: WADA: acetyl tetrapeptide-5 was not identified by exact name in the 2026 Prohibited List, and this review did not identify a matching prohibited class for the topical cosmetic use described here. Absence of an exact-name entry is not blanket permission; athletes should check the exact product, route, and current List with their anti-doping organisation.

Mechanism and pharmacology

Acetyl tetrapeptide-5 is proposed to reduce periorbital edema by inhibiting angiotensin-converting enzyme (ACE), thereby reducing vascular permeability and fluid accumulation in the periorbital tissues. It also inhibits non-enzymatic glycation of dermal proteins (anti-glycation activity). The manufacturer reports that the peptide binds to the active site of ACE in vitro. The histidine residues in the sequence are thought to coordinate the zinc ion at the ACE active site, similar to known ACE-inhibitory peptides derived from food proteins. The anti-glycation mechanism has been demonstrated in model systems but not in human skin in vivo with clinically relevant endpoints. The dual-mechanism claim (ACE inhibition + anti-glycation) has not been independently replicated for the topical cosmetic use case.

Evidence by claim

Claim/indication	Stage	Grade	Best human evidence	Main result	Important limitations
Reduction of under-eye puffiness	Cosmetic	C	Manufacturer study: 20 volunteers, 10% Eyeseryl, 60 days	70% improved by day 15, 95% by day 60	Uncontrolled, small N, manufacturer sponsorship, subjective grading
Anti-glycation	Cosmetic	D	In vitro only	Inhibition of glycation in model systems	No human skin confirmation; clinical relevance unclear
ACE inhibition in skin	Cosmetic	D	In vitro binding data	ACE active-site binding	No in vivo confirmation after topical application

साक्ष्य ग्रेड

Aग्रेड A: विशिष्ट लेबल वाले उपयोग के लिए स्थापित
Bग्रेड B: मध्यम मानव साक्ष्य
Cग्रेड C: प्रारंभिक मानव साक्ष्य
Dग्रेड D: केवल प्रीक्लिनिकल
Eग्रेड E: उपाख्यानात्मक/विपणन दावा
Xग्रेड X: साक्ष्य दावे का खंडन करता है या समर्थन नहीं करता

साक्ष्य ग्रेडिंग के बारे में और जानें

Claim-evidence profile

This counts the page's claim rows; it does not average them into a score.

पाठ विकल्प

Text alternative for the claim-evidence diagram. Each grade is defined below:

A — Established for a specific labeled use: 0 claims
B — Moderate human evidence: 0 claims
C — Preliminary human evidence: 1 claim: Reduction of under-eye puffiness
D — Preclinical only: 2 claims: Anti-glycation; ACE inhibition in skin
E — Anecdotal/marketing claim: 0 claims
X — Evidence contradicts or does not support the claim: 0 claims

United StatesRegulated as a cosmetic ingredient under the FD&C Act; not approved as a drugNo standalone Cosmetic Ingredient Review safety assessment for acetyl tetrapeptide-5 was identified in the sources searched; no CIR conclusion is inferred

EU/EEAListed in the CosIng inventory; an INCI listing is an inventory entry, not a regulatory authorisation or safety approvalNo specific SCCS safety opinion; covered under general provisions of EU Cosmetics Regulation EC 1223/2009

Key studies

Study	Design/population	Exposure studied	Endpoints and result	Limitations
Lubrizol (Eyeseryl product dossier)	, 20 healthy female volunteers	Formulation described as 10% Eyeseryl solution, used twice daily periorbitally for 60 days	Clinical grading of puffiness by dermatologist: 70% improved at day 15, 95% at day 60	Uncontrolled; single-centre; small N; active-peptide concentration not independently established; no blinded or independent assessment; no control
In vitro ACE inhibition	Enzyme assay	Peptide concentrations 0.1–100 µM	Dose-dependent ACE inhibition	Not replicated in vivo; relevance to topical application untested

Dose and administration evidence

Approved labeled regimen

Acetyl tetrapeptide-5 is a cosmetic ingredient, not an approved drug. No established or recommended human dose.

Studied regimens (not recommendations)

One manufacturer-sponsored study described a formulation containing 10% Eyeseryl solution applied periorbitally twice daily for 60 days. This is a descriptive study exposure, not a recommended regimen, and the study did not independently establish the concentration of active acetyl tetrapeptide-5.

What is not established

No established or recommended human dose.

Safety

Established label risks

Not applicable.

Human-study signals

The manufacturer dossier does not describe a clear adverse-event signal in the 20-volunteer report. That absence of reporting is not evidence of safety and no independent controlled tolerability study was identified.

Unknowns and product-quality risks

Not established for injection or internal use
ACE-inhibitory activity raises theoretical concern if systemically absorbed or injected, but topical application at cosmetic concentrations is not expected to produce systemic blood-pressure effects
No chronic-dermal-exposure data beyond 60 days
No irritation/sensitization data in controlled patch tests published in peer-reviewed literature

Interactions and special populations

No known interactions from topical use
No pregnancy/lactation safety data

Regulatory, compounding, and sport notes

EU CosIng: listed in the cosmetic ingredient inventory (INCI entry; does not constitute regulatory approval)
US: regulated as a cosmetic ingredient; no FDA drug approval
: acetyl tetrapeptide-5 was not identified by exact name in the 2026 Prohibited List, and this review did not identify a matching prohibited class for the topical cosmetic use described here. Absence of an exact-name entry is not blanket permission; athletes should check the exact product, route, and current List with their anti-doping organisation.
Often sold in "research peptide" catalogs labelled as Eyeseryl; any injection or parenteral use would be outside the assessed safety and efficacy profile

Evidence gaps

No independent clinical trials; single manufacturer-sponsored study only
No studies comparing to established treatments for periorbital edema (e.g., caffeine-based creams, cold compresses)
ACE-inhibitory activity in vivo after topical application not characterized
Anti-glycation efficacy in human skin not demonstrated
Formulation-dependent activity: efficacy data from 10% Eyeseryl solution cannot be generalized to other formulations
No peer-reviewed, PubMed-indexed clinical trial identified as of searched date

Search notes

Databases and registries: PubMed, EU CosIng, PubChem, FDA UNII, CAS Common Chemistry, Cosmetic Ingredient Review ingredient/publication search
Search terms: "acetyl tetrapeptide-5", "Eyeseryl", "Ac-βAla-His-Ser-His", "acetyl-β-alanyl-histidyl-seryl-histidine"
Last searched: 2026-08-06
Inclusion emphasis: regulatory status, identity records, safety profile, clinical evidence
PubMed search 2026-08-06: no results for "acetyl tetrapeptide-5 clinical trial" or "Eyeseryl clinical trial" in indexed peer-reviewed journals

Sources

EU CosIng. Acetyl Tetrapeptide-5 (ref 54142). https://ec.europa.eu/growth/tools-databases/cosing/
UNII Y1DFQ308G8. https://precision.fda.gov/uniisearch/srs/unii/Y1DFQ308G8
Lubrizol. Eyeseryl peptide solution G product information. https://www.lubrizol.com/solutions/products/beauty/detail-pages/eyeseryl-peptide-solution-g
World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
CAS Common Chemistry. Acetyl tetrapeptide-5 (CAS 820959-17-9). https://commonchemistry.cas.org/detail?cas_rn=820959-17-9
FDA UNII Y1DFQ308G8. https://precision.fda.gov/uniisearch/srs/unii/Y1DFQ308G8
EU CosIng ingredient database (ref 54142). https://ec.europa.eu/growth/tools-databases/cosing/

विशेषज्ञों की राय

विशेषज्ञ क्या कहते हैं

टिप्पणियाँ व्यक्तिगत राय हैं, साक्ष्य समीक्षा का हिस्सा नहीं; समावेश का अर्थ समर्थन नहीं है।

इस यौगिक के लिए इस एटलस द्वारा स्वीकृत स्रोतों — सहकर्मी-समीक्षित साहित्य, विश्वविद्यालय, अस्पताल और चिकित्सा समाज संचार, नियामक, और नामांकित वैज्ञानिक पत्रकारिता — में कोई सत्यापित विशेषज्ञ टिप्पणी नहीं मिली।

टिप्पणी का अभाव यौगिक के बारे में किसी भी दिशा में साक्ष्य नहीं है।

विक्रेता, क्लिनिक और सोशल मीडिया के दावे नीति द्वारा बाहर रखे गए हैं और टिप्पणी के रूप में नहीं गिने जाते।

इस यौगिक के लिए इस एटलस के स्रोतों में कोई सत्यापित विशेषज्ञ वीडियो नहीं मिला।

वीडियो टिप्पणी का अभाव यौगिक के बारे में किसी भी दिशा में साक्ष्य नहीं है।

विक्रेता और सोशल मीडिया के वीडियो नीति द्वारा बाहर रखे गए हैं और नहीं गिने जाते।

प्रश्न

What is acetyl tetrapeptide-5?

Acetyl tetrapeptide-5 (INCI name; trade name Eyeseryl) is a synthetic acetylated tetrapeptide (Ac-βAla-His-Ser-His) developed by Lipotec/Lubrizol for periorbital cosmetic use. Its proposed mechanisms are ACE inhibition to reduce vascular permeability and anti-glycation activity targeting tissue stiffening under the eyes. Eyeseryl is a trade name for a formulated solution containing the peptide, not the pure substance.

Is acetyl tetrapeptide-5 FDA-approved?

Acetyl tetrapeptide-5 has no FDA drug approval. It is regulated as a cosmetic ingredient under the FD&C Act and listed in EU CosIng as a humectant. No standalone CIR safety assessment was identified.

Does acetyl tetrapeptide-5 reduce under-eye puffiness?

Acetyl tetrapeptide-5 is a cosmetic ingredient, not an approved drug; no established or recommended human dose exists. The sole human evidence is a manufacturer-sponsored open-label study of 20 volunteers using Eyeseryl for periorbital cosmetic use. It reported improvement in under-eye puffiness at day 15 and day 60 based on dermatologist grading. This is a descriptive study exposure, not a recommendation. The study was uncontrolled, small, and the active-peptide concentration was not independently established.

Why does the exact product and formulation matter when reading acetyl tetrapeptide-5 evidence?

Eyeseryl is a formulated solution containing acetyl tetrapeptide-5, not the pure peptide. No established or recommended human dose exists. The sole human study described use of a formulation containing Eyeseryl; this is a descriptive study exposure, not a recommendation. The concentration of active acetyl tetrapeptide-5 was not independently established and results from that formulation cannot be generalised to other formulations. The monograph supplies CAS 820959-17-9 and UNII Y1DFQ308G8 for the peptide; it supplies no separate identifiers for Eyeseryl.

Why must findings for acetyl tetrapeptide-5 be matched to the exact claim?

The strongest evidence is Grade C for reduction of under-eye puffiness based on a single uncontrolled manufacturer-sponsored study. That Grade C applies only to the cosmetic endpoint studied; it does not establish efficacy for anti-glycation or ACE inhibition in the skin, which have only in vitro support (Grade D). The product also lacks FDA drug approval.

What remains unknown about acetyl tetrapeptide-5?

There are no independent clinical trials; only a single manufacturer-sponsored study exists. In vivo ACE-inhibitory activity after topical application has not been characterised, and anti-glycation efficacy in human skin has not been demonstrated. No peer-reviewed, PubMed-indexed clinical trial was identified as of the searched date.

अनुसंधान अद्यतन

एटलस से जुड़ें. साक्ष्य अद्यतन प्राप्त करें.

पेप्टाइड साक्ष्य, स्थिति, या स्रोत रिकॉर्ड बदलने पर संक्षिप्त नोट्स प्राप्त करें।

एक नज़र में

01 —Bottom line

02 —Identity and composition

03 —Development and approval status

04 —Mechanism and pharmacology

05 —Evidence by claim

06 —Key studies

07 —Dose and administration evidence